Some of the names on the move ahead of the open.» Read More
The candidate Ebola vaccine is being co-developed by the United States National Institutes of Health and the British drugmaker GlaxoSmithKline. The trial will be led by Professor Adrian Hill of the Jenner Institute at Oxford University, which said on Friday the first shot is scheduled to be given to a human volunteer next week.
LONDON/ NEW YORK, Sept 12- As electronic cigarettes flew off shelves on both sides of the Atlantic in recent years, investors flocked to a business some hope will be the future for tobacco.
The worst-ever Ebola outbreak, which has already killed at least 2,296 people in West Africa, has triggered a scramble to develop the first drug or vaccine for a deadly disease that was discovered nearly 40 years ago in the forests of central Africa.
JOHANNESBURG, Sept 10- Aspen Pharmacare is to sell the rights to market a blood clot drug in the United States to rival Mylan Inc for up to $300 million, it said on Wednesday, a move that would help Africa's top generic drugmaker pay down debt.
SHANGHAI/ WASHINGTON, Sept 9- A U.S. anti-bribery probe into GlaxoSmithKline Plc touched on the firm's Chinese consumer healthcare business in 2012, internal documents show, suggesting the drugmaker's compliance problems in China could go wider than previously revealed.
Sept 4- NewLink Genetics Corp said the U.S. Food and Drug Administration allowed the company to start testing an experimental Ebola vaccine in humans. The move follows a decision to begin initial human testing of a GlaxoSmithKline vaccine this month and an approval to fast track tests of a Johnson& Johnson vaccine.
Sept 3- Chimerix Inc said its lead experimental drug showed promise against the deadly Ebola virus in laboratory testing at the U.S. Centers for Disease Control and Prevention and the National Institutes of Health.
Sept 2- The U.S. Department of Health and Human Services said on Tuesday a federal contract worth up to $42.3 million would help accelerate testing of an experimental Ebola virus treatment that is being developed by privately held Mapp Biopharmaceutical Inc..
LONDON, Aug 31- British newspapers reported the following business stories on Sunday. GlaxoSmithKline is facing a shareholder revolt over plans to shake up its board, with leading investors calling for the speedy departure of Chairman Christopher Gent.
The success is therefore a "monumental achievement," virologist Thomas Geisbert of the University of Texas Medical Branch wrote in a commentary on the paper, published online in Nature.
Aug 29- BioCryst Pharmaceuticals Inc said it expects to initiate a study within weeks to test its antiviral in primates for use against Ebola infections. This $2.4 million National Institute of Allergy and Infectious Diseases funding is in addition to the $22 million contract awarded to BioCryst by the agency last September.
His crime was contributing to research that led his employer to recommend short sales of Silvercorp Metals, a silver producer that is based in Canada but does its mining in China.
CHICAGO, Aug 28- Genetic studies of some of the earliest Ebola cases in Sierra Leone reveal more than 300 genetic changes in the virus as it leapt from person to person, changes that could blunt the effectiveness of diagnostic tests and experimental treatments now in development, researchers said on Thursday.
GENEVA/ LAGOS Aug 28- The Ebola epidemic in West Africa could infect more than 20,000 people, the U.N. health agency said on Thursday, warning that an international effort costing almost half a billion dollars is needed to overcome the outbreak.
Some of the names on the move ahead of the open.
LONDON/ NEW YORK, Aug 28- An experimental Ebola vaccine from GlaxoSmithKline is being fast-tracked into human studies and the company plans to build a stockpile of up to 10,000 doses for emergency deployment, if results are good.
WINNIPEG, Manitoba, Aug 25- Four monkeys survived the Ebola virus after being injected with a vaccine that included Immunovaccine Inc's technology, the tiny Canadian company said on Monday, and the announcement sent its stock soaring.
The long-anticipated settlement is expected to consist of a penalty of $9.6 billion and a package of consumer-relief measures valued at $7 billion.
*Drug has orphan drug status in US, EU and Japan. Aug 20- Amicus Therapeutics Inc moved a step closer to bringing its first drug to the market after trial results paved the way for its lead drug to become the first oral treatment for patients with a disorder that causes an abnormal build-up of fat.
Aug 20- Amicus Therapeutics Inc said its experimental drug was as effective as enzyme replacement therapies after 18 months in patients with Fabry disease, an inherited disorder that leads to the abnormal build-up of fat. The company's stock rose 38 percent in premarket trading on Wednesday after the results of the second late-stage trial were released.